Bausch + Lomb Corporation (BLCO) AI Stock Analysis

• Market Cap: $6.13B
• Dividend Yield: N/A
• Average Volume (3M): 405.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 6.23%
• EPS Growth: 17.53%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.18
• Shares Outstanding: 354,189,800
• 10 Day Avg. Volume: 391,487
• 30 Day Avg. Volume: 405,477
• PEG Ratio: -0.93
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 1.33
• P/FCF Ratio: -107.69
• Enterprise Value/Market Cap: 1.64
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 3.39
• Enterprise Value/Ebitda: 19.70
• 1Y Price Target: $17.36
• Price Target Upside: 0.37% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $17.50 ▲(1.16% Upside)

Overall score reflects a balance between weak underlying financial performance (losses and negative free cash flow) and a more positive forward narrative from the earnings call (solid segment-led revenue growth and maintained guidance). Technicals are neutral-to-mildly supportive, while valuation is constrained by the negative P/E and lack of dividend yield data; corporate actions modestly improve the outlook via refinancing and governance upgrades.

Positive Factors

Revenue Growth

Consistent revenue growth across all segments indicates strong market demand and effective business strategies, supporting long-term expansion.

Strategic Growth Plan

The strategic growth plan focuses on innovation and sustainable growth, positioning the company for long-term success and competitive advantage.

Board Strengthening

The addition of experienced directors enhances strategic oversight and operational expertise, supporting the company's growth and innovation goals.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder reinvestment and shareholder returns, impacting long-term financial health and growth potential.

Cash Flow Weakness

Weak cash flow limits the company's ability to fund operations and growth initiatives, potentially affecting its financial stability and strategic flexibility.

Gross Margin Decline

Declining gross margins reflect cost pressures and operational inefficiencies, which could erode profitability and competitive positioning over time.

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

How the Company Makes Money

Bausch + Lomb generates revenue through several key streams, including the sale of contact lenses and lens care products, surgical products, and pharmaceutical solutions for eye health. The contact lens segment, which includes daily disposable and specialty lenses, represents a significant portion of the company's income. Additionally, the surgical division, which provides equipment and consumables for cataract and refractive surgery, contributes to its earnings. The company also engages in partnerships with healthcare providers and distributors to expand its market reach and enhance its product offerings. Furthermore, Bausch + Lomb invests in research and development to innovate new products, which helps maintain its competitive edge and drive long-term revenue growth.

Bausch + Lomb Corporation Financial Statement Overview

Summary

Bausch + Lomb Corporation faces challenges in profitability and cash flow, despite stable revenue growth and a solid equity base. The company needs to improve operational efficiency and cash generation to enhance financial health and shareholder returns.

Income Statement

Bausch + Lomb Corporation shows modest revenue growth in the TTM, but profitability remains a concern with negative net profit margins. The gross profit margin is stable, indicating efficient cost management, but the EBIT and EBITDA margins have declined, reflecting operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate, suggesting a balanced approach to leveraging. However, the negative return on equity indicates challenges in generating returns for shareholders. The equity ratio is healthy, showing a strong equity base relative to total assets.

Cash Flow

Cash flow performance is weak, with negative free cash flow and low operating cash flow coverage. The free cash flow to net income ratio is concerning, highlighting cash generation issues. Despite some growth in free cash flow, overall cash flow stability is lacking.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.98B	4.79B	4.15B	3.77B	3.77B	3.41B
Gross Profit	2.96B	2.92B	2.50B	2.25B	2.30B	2.13B
EBITDA	509.00M	601.00M	499.00M	598.00M	733.00M	732.00M
Net Income	-305.00M	-317.00M	-260.00M	6.00M	182.00M	-18.00M
Balance Sheet
Total Assets	13.83B	13.47B	13.44B	11.14B	10.82B	11.27B
Cash, Cash Equivalents and Short-Term Investments	310.00M	305.00M	334.00M	380.00M	174.00M	238.00M
Total Debt	4.95B	4.94B	4.68B	2.55B	140.00M	101.00M
Total Liabilities	7.33B	6.92B	6.52B	4.04B	1.42B	1.28B
Stockholders Equity	6.43B	6.47B	6.85B	7.03B	9.33B	9.92B
Cash Flow
Free Cash Flow	-194.47M	-59.00M	-198.00M	170.00M	680.00M	263.00M
Operating Cash Flow	171.05M	232.00M	-17.00M	345.00M	873.00M	522.00M
Investing Cash Flow	-452.30M	-412.00M	-2.11B	-215.00M	-214.00M	-256.00M
Financing Cash Flow	254.45M	178.00M	2.08B	81.00M	-712.00M	-232.00M

Bausch + Lomb Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Positive. The current price of 17.3 is above the 20-day moving average (MA) of 17.03, above the 50-day MA of 16.28, and above the 200-day MA of 14.22, indicating a bullish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 59.92 is Neutral, neither overbought nor oversold. The STOCH value of 85.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLCO.

Bausch + Lomb Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	77 Outperform	$5.52B	47.69	8.30%	―	11.49%	-2.89%
COO	77 Outperform	$16.29B	44.36	4.59%	―	5.06%	-4.47%
RGEN	67 Neutral	$9.37B	6,475.49	0.08%	―	11.74%	―
STVN	67 Neutral	$5.75B	37.02	9.81%	0.29%	9.19%	23.06%
BLCO	55 Neutral	$6.13B	-20.03	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	46 Neutral	$2.49B	-2.82	-44.44%	5.61%	-7.08%	-113.81%

Bausch + Lomb Corporation Corporate Events

Bausch + Lomb refinances term loans, extends maturities

On January 2, 2026, Bausch + Lomb Corporation closed a refinancing of its existing credit facilities by entering into a fourth amendment to its credit agreement, establishing a new $2.80 billion tranche of term B loans maturing on January 15, 2031. The proceeds were used to refinance all of the company’s outstanding term B loans due 2031 and 2028, effectively extending the maturity of the 2028 loans to 2031 while lowering borrowing costs by reducing the applicable margins by 0.50 percentage points and 0.25 percentage points, respectively; the new loans amortize at 1.00% per year starting June 30, 2026, signaling an effort to optimize Bausch + Lomb’s capital structure and potentially improve its interest expense profile over time.

The most recent analyst rating on (BLCO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Adds New Directors to Board

On December 17, 2025, Bausch + Lomb Corporation announced the appointment of Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. These appointments follow board changes announced in August 2025 and bring renowned expertise to the company, with Dr. Alfonso’s leadership in ophthalmology and Mr. Collis’s significant contributions to the pharmaceutical sector. The additions aim to strengthen Bausch + Lomb’s strategic direction and operations as it pursues growth opportunities across the eye health industry.

The most recent analyst rating on (BLCO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Unveils Strategic Growth Plan at Investor Day

On November 13, 2025, Bausch + Lomb Corporation announced its plans during an Investor Day event at the New York Stock Exchange, highlighting a transformation in its operations and a focus on sustainable growth. The company revealed a three-year plan targeting above-market revenue growth and margin expansion, driven by innovations in its eye health product pipeline. The event emphasized Bausch + Lomb’s commitment to leveraging AI and new technologies, with projected peak sales of pipeline products expected to reach approximately $7 billion. The company aims for a 5-7% revenue CAGR through 2028, with significant product launches anticipated across various segments, reaffirming its 2025 guidance and positioning itself for long-term value creation for shareholders.

The most recent analyst rating on (BLCO) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.